Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 5981432, 6 pages
https://doi.org/10.1155/2017/5981432
Research Article

A Potential of sFasL in Preventing Gland Injury in Sjogren’s Syndrome

1Department of Rheumatology and Clinical Immunology, The First Hospital of Xiamen University, Xiamen 361003, China
2Xiamen Key Laboratory of Rheumatology and Clinical Immunology, Xiamen, China
3The Chenggong Hospital Affiliated to Xiamen University, Xiamen, Fujian, China

Correspondence should be addressed to Yan He; moc.qq@nayehwollaws and Guixiu Shi; nc.ude.umx@ihsg

Received 26 October 2016; Accepted 6 February 2017; Published 23 February 2017

Academic Editor: Xiaoquan Rao

Copyright © 2017 Jiao Luo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. N. Skopouli, U. Dafni, J. P. A. Ioannidis, and H. M. Moutsopoulos, “Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome,” Seminars in Arthritis and Rheumatism, vol. 29, no. 5, pp. 296–304, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. A. S. Malladi, K. E. Sack, S. C. Shiboski et al., “Primary Sjögren's syndrome as a systemic disease: a study of participants enrolled in an International Sjögren's syndrome registry,” Arthritis Care & Research, vol. 64, no. 6, pp. 911–918, 2012. View at Publisher · View at Google Scholar
  3. C. P. Mavragani and H. M. Moutsopoulos, “The geoepidemiology of Sjögren's syndrome,” Autoimmunity Reviews, vol. 9, no. 5, pp. A305–A310, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Lindgren, R. Manthorpe, and S. Eriksson, “Autoimmune liver disease in patients with primary Sjögren's syndrome,” Journal of Hepatology, vol. 20, no. 3, pp. 354–358, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. G. S. Hatzis, G. E. Fragoulis, A. Karatzaferis, I. Delladetsima, C. Barbatis, and H. M. Moutsopoulos, “Prevalence and longterm course of primary biliary cirrhosis in primary Sjögren's syndrome,” Journal of Rheumatology, vol. 35, no. 10, pp. 2012–2016, 2008. View at Google Scholar · View at Scopus
  6. M. Ramos-Casals, J.-M. Sánchez-Tapias, A. Parés et al., “Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjögren's syndrome,” Journal of Rheumatology, vol. 33, no. 8, pp. 1593–1599, 2006. View at Google Scholar · View at Scopus
  7. S. Yonehara, A. Ishii, and M. Yonehara, “A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor,” Journal of Experimental Medicine, vol. 169, no. 5, pp. 1747–1756, 1989. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Takahashi, M. Tanaka, J. Inazawa, T. Abe, T. Suda, and S. Nagata, “Human fas ligand: gene structure, chromosomal location and species specificity,” International Immunology, vol. 6, no. 10, pp. 1567–1574, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Nagata and P. Golstein, “The fas death factor,” Science, vol. 267, no. 5203, pp. 1449–1456, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. P. H. Krammer, J. Dhein, H. Walczak et al., “The role of APO-1-mediated apoptosis in the immune system,” Immunological Reviews, vol. 142, pp. 175–191, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. M. R. Alderson, T. W. Tough, T. Davis-Smith et al., “Fas ligand mediates activation-induced cell death in human T lymphocytes,” Journal of Experimental Medicine, vol. 181, no. 1, pp. 71–77, 1995. View at Publisher · View at Google Scholar
  12. D. Bellgrau, D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R. C. Duke, “A role for CD95 ligand in preventing graft rejection,” Nature, vol. 377, no. 6550, pp. 630–632, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. T. S. Griffith, T. Brunner, S. M. Fletcher, D. R. Green, and T. A. Ferguson, “Fas ligand-induced apoptosis as a mechanism of immune privilege,” Science, vol. 270, no. 5239, pp. 1189–1192, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. J. S. Hunt, D. Vassmer, T. A. Ferguson, and L. Miller, “Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus,” Journal of Immunology, vol. 158, no. 9, pp. 4122–4128, 1997. View at Google Scholar · View at Scopus
  15. P. G. Knox, A. E. Milner, N. K. Green, A. G. Eliopoulos, and L. S. Young, “Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand,” The Journal of Immunology, vol. 170, no. 2, pp. 677–685, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Li, H. Nie, Q.-W. Yu et al., “Role of soluble Fas ligand in autoimmune diseases,” World Journal of Gastroenterology, vol. 10, no. 21, pp. 3151–3156, 2004. View at Publisher · View at Google Scholar
  17. R.-P. Jia and X.-Y. Zhao, “[Expression and clinical significance of CD4(+)CD25(+)Treg cells, sFas and sFasL in peripheral blood of patients with autoimmune thrombocytopenic purpura],” Zhongguo shi yan xue ye xue za zhi, vol. 19, no. 5, pp. 1264–1267, 2011. View at Google Scholar · View at Scopus
  18. C. Vitali, S. Bombardieri, R. Jonsson et al., “Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group,” Annals of the Rheumatic Diseases, vol. 61, no. 6, pp. 554–558, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Vitali, G. Palombi, C. Baldini et al., “Sjögren's syndrome disease damage index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients,” Arthritis and Rheumatism, vol. 56, no. 7, pp. 2223–2231, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Hernández-Molina and T. Sánchez-Hernández, “Clinimetric methods in Sjögren's syndrome,” Seminars in Arthritis and Rheumatism, vol. 42, no. 6, pp. 627–639, 2013. View at Publisher · View at Google Scholar
  21. R. Seror, J. E. Gottenberg, V. Devauchelle-Pensec et al., “European league against Rheumatism Sjögren's syndrome disease activity index and European League Against Rheumatism Sjögren's syndrome patient-reported index: a complete picture of primary Sjögren's syndrome patients,” Arthritis Care and Research, vol. 65, no. 8, pp. 1358–1364, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. E. H. Kang, Y. J. Lee, J. Y. Hyon, P. Y. Yun, and Y. W. Song, “Salivary cytokine profiles in primary Sjögren's syndrome differ from those in non-Sjögren sicca in terms of TNF-α levels and Th-1/Th-2 ratios,” Clinical and Experimental Rheumatology, vol. 29, no. 6, pp. 970–976, 2011. View at Google Scholar · View at Scopus
  23. M. D. Mignogna, S. Fedele, L. Lo Russo, L. Lo Muzio, and A. Wolff, “Sjögren's syndrome: the diagnostic potential of early oral manifestations preceding hyposalivation/xerostomia,” Journal of Oral Pathology and Medicine, vol. 34, no. 1, pp. 1–6, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Nozawa, N. Kayagaki, Y. Tokano, H. Yagita, K. Okumura, and H. Hasimoto, “Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases,” Arthritis and Rheumatism, vol. 40, no. 6, pp. 1126–1129, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Musiał and D. Zwolińska, “The sFas/sFasL ratio as a novel marker of inflammation in children with chronic kidney disease,” Clinica Chimica Acta, vol. 414, pp. 7–11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Haddad, J.-C. Trinchet, D. Pateron et al., “Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease,” The Lancet, vol. 339, no. 8789, pp. 321–323, 1992. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Xanthou, N. I. Tapinos, M. Polihronis, I. P. Nezis, L. H. Margaritis, and H. M. Moutsopoulos, “CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjogren's syndrome,” Clinical and Experimental Immunology, vol. 118, no. 1, pp. 154–163, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Bodeutsch, P. C. M. De Wilde, L. Kater et al., “Monotypic plasma cells in labial salivary glands of patients with Sjogren's syndrome: prognosticator for systemic lymphoproliferative disease,” Journal of Clinical Pathology, vol. 46, no. 2, pp. 123–128, 1993. View at Publisher · View at Google Scholar · View at Scopus
  29. D. I. Stott, F. Hiepe, M. Hummel, G. Steinhauser, and C. Berek, “Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome,” Journal of Clinical Investigation, vol. 102, no. 5, pp. 938–946, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Dörner and P. E. Lipsky, “Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjögren's syndrome,” Arthritis Research, vol. 4, no. 6, pp. 360–371, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. A. N. Akbar, N. Borthwick, M. Salmon et al., “The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory,” Journal of Experimental Medicine, vol. 178, no. 2, pp. 427–438, 1993. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Scaffidi, I. Schmitz, J. Zha, S. J. Korsmeyer, P. H. Krammer, and M. E. Peter, “Differential modulation of apoptosis sensitivity in CD95 type I and type II cells,” Journal of Biological Chemistry, vol. 274, no. 32, pp. 22532–22538, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. A. K. Vaishnaw, J. D. McNally, and K. B. Elkon, “Apoptosis in the rheumatic diseases,” Arthritis and Rheumatism, vol. 40, no. 11, pp. 1917–1927, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Ogawa, H. Dang, L. Kong, J.-M. Anaya, G. T. Liu, and N. Talal, “Lymphocyte apoptosis and apoptosis-associated gene expression in sjogren's syndrome,” Arthritis and Rheumatism, vol. 39, no. 11, pp. 1875–1885, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Rogge, X.-T. Yin, L. Godfrey et al., “Therapeutic use of soluble fas ligand ameliorates acute and recurrent herpetic stromal keratitis in mice,” Investigative Ophthalmology and Visual Science, vol. 56, no. 11, pp. 6377–6386, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Perosso, K. L. O. Silva, S. Í. D. S. Ferreira et al., “Alteration of sFAS and sFAS ligand expression during canine visceral leishmaniosis,” Veterinary Parasitology, vol. 205, no. 3-4, pp. 417–423, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Qin, P. Liao, S. He et al., “Detection of FasL mRNA, sFasL and their regulatory effect on T lymphocyte subsets in patients with severe acute pancreatitis,” Chinese Journal of Cellular and Molecular Immunology, vol. 29, no. 11, pp. 1189–1192, 2013. View at Google Scholar · View at Scopus
  38. N. Amft and S. J. Bowman, “Chemokines and cell trafficking in Sjögren's syndrome,” Scandinavian Journal of Immunology, vol. 54, no. 1-2, pp. 62–69, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Li-Weber and P. H. Krammer, “Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system,” Seminars in Immunology, vol. 15, no. 3, pp. 145–157, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Miyawaki, T. Uehara, R. Nibu et al., “Differential expression of apoptosis-related fas antigen on lymphocyte subpopulations in human peripheral blood,” Journal of Immunology, vol. 149, no. 11, pp. 3753–3758, 1992. View at Google Scholar · View at Scopus
  41. I. Schmitz, A. Krueger, S. Baumann, H. Schulze-Bergkamen, P. H. Krammer, and S. Kirchhoff, “An IL-2-dependent switch between CD95 signaling pathways sensitizes primary human T cells toward CD95-mediated activation-induced cell death,” Journal of Immunology, vol. 171, no. 6, pp. 2930–2936, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. C.-L. Wu, Q. Wang, L. Zheng, D.-Y. Gu, J.-A. He, and C.-P. Shao, “[Correlation of Breg with CD4(+)T cells of peripheral blood in patients with CITP and its clinical significance],” Journal of experimental hematology/Chinese Association of Pathophysiology, vol. 21, no. 6, pp. 1517–1521, 2013. View at Google Scholar · View at Scopus
  43. K. Yanaba, J.-D. Bouaziz, K. M. Haas, J. C. Poe, M. Fujimoto, and T. F. Tedder, “A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses,” Immunity, vol. 28, no. 5, pp. 639–650, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Uehara, T. Miyawaki, K. Ohta et al., “Apoptotic cell death of primed CD45RO+ T lymphocytes in Epstein-Barr virus-induced infectious mononucleosis,” Blood, vol. 80, no. 2, pp. 452–458, 1992. View at Google Scholar · View at Scopus
  45. J. Estaquier, T. Idziorek, W. Zou et al., “T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons,” Journal of Experimental Medicine, vol. 182, no. 6, pp. 1759–1767, 1995. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Roth, B. Moser, C. Krenn et al., “Susceptibility to programmed cell death in T-lymphocytes from septic patients: a mechanism for lymphopenia and Th2 predominance,” Biochemical and Biophysical Research Communications, vol. 308, no. 4, pp. 840–846, 2003. View at Publisher · View at Google Scholar · View at Scopus